New data link low-dose mTOR inhibition to DNA pr

Once-a-month shot delivers meaningful weight los

Company’s osteoporosis program completes enrol

Phase 1 dosing milestone for MEN2501 signals gro

Light-activated skin therapy highlights why long

The global oncolytic virus therapy landscape has

LifeVantage Corporation reported its financial re

Cognision has launched Cognision360, a web-based

Telomir Pharmaceuticals, a Miami-based preclinica

New industry data outlines the financial performa

Ambr founder on how the startup is targeting pop

Dutch biotech and leading neuroscience lab team

Fresh capital signals growing belief in preventi

Investors show appetite for Veradermics’ exten

Research shows stopping GLP-1 weight-loss drugs

Isaac Health, a telehealth-based brain health and

Abinopharm, Inc.

Alzheon said that plasma biomarker analyses from

dōTERRA International, LLC, the global leader in

Insilico Medicine said that it has received a USD

Longevity Investors Lunch reflects a maturing fi

Luffu targets collective health and wellbeing ac

A newly identified inflammatory ‘workaround’

Fresh Series A backs a hybrid model blending hum

Jupiter Neurosciences, Inc.

Gameto, a clinical‑stage biotechnology company

Acorn Biolabs said it has treated the first patie

New funding taps human-brain data to track a pro

EMA recommends semaglutide for fatty liver disea

Death Clock adds AI-powered blood biomarker anal

As psychedelics emerge as tools for cognitive re

Big pharma AstraZeneca partners with Hong Kong’s CSPC to develop next-gen weight management drugs worldwide. Managing your weight is possible without complicated schedules, multiple pills or daily injections. That’s the vision British-Swedish pharma giant AstraZeneca is chasing with its latest move: a massive $18.5 billion licensing deal with Hong Kong-based CSPC Pharmaceutical Group to develop and commercialize cutting-edge obesity drugs outside China, Hong Kong, Macao and Taiwan [1]. The core of the deal is SYH2082, an injectable drug candidate that’s ready for clinical trials, along with several other programs designed to make weight loss more consistent, effective and patient-friendly. AstraZeneca is paying $1.2 billion upfront, with the potential for another $17.3 billion if the treatments hit development and sales milestones. “This strategic collaboration advances our weight management portfolio by delivering novel assets which complement our existing programmes,” said Sharon Barr, PhD, AstraZeneca’s head of biopharmaceuticals R&D [1]. “It will provide access to CSPC’s proprietary AI-enabled peptide capabilities and platform technology, which have the potential to transform the treatment of obesity.” Obesity isn’t just about fitting into your favorite jeans. It’s a silent contributor to conditions that shave years off our lives, like type 2 diabetes, heart disease and certain chronic…

First patient dosing signals growing confidence

Pre-seed funding will help Xella build tools tha

From peptides to stem cells, a physician shows h

Preclinical results spotlight a new AI-driven ap

New research maps the slow cascade from brief ta

Company initially targets ‘exosome-based welln

Drug could offer weekly at-home injections, simp

Mesoblast Limited, a global developer of allogene

ProMIS Neurosciences Inc.

NeuroEM Therapeutics, a clinical-stage biotechnol

Illumina, Inc.

GenSight Biologics S.A.

Fractyl Health, Inc.

A commentary issued on behalf of VentriPoint Diag

Alterity Therapeutics Ltd.

Correcting for extrinsic mortality suggests intr

Corsera COO explains why the biotech is building

Altimmune raises $75 million to advance pemvidut